Scarica l'app Stockscreener
3.08
4.35%
-0.14
Dopo l'orario di chiusura:
3.02
-0.06
-1.95%
Vivos Therapeutics Inc Borsa (VVOS) Ultime notizie
Vivos surges on FDA nod for pediatric sleep apnea device - MSN
You might want to take a look at Vivos Therapeutics Inc (VVOS) now - SETE News
Vivos Therapeutics announces $4.3 million stock sale By Investing.com - Investing.com Canada
Vivos Therapeutics announces $4.3 million stock sale - Investing.com
VVOS’s price-to-cash ratio: How it affects the stock’s valuation. - US Post News
Vivos Therapeutics Shares Drop 27% After Pricing of Common Stock Offering - MarketWatch
Why Vivos Therapeutics (VVOS) Stock Is Down 25% Today - Benzinga
Vivos Therapeutics announces $4.3 million stock sale By Investing.com - Investing.com Australia
Nasdaq Surges 400 Points; US Jobless Claims Fall To 219,000 - Benzinga
Vivos Therapeutics Announces Pricing of $4.3 Million Registered Direct Offering of Common Stock Priced At-The-Market Under Nasdaq Rules - StockTitan
Vivos Therapeutics raises $4.3 from institutional investors - Proactive Investors USA
Nvidia, T-Mobile US, Vivos Therapeutics, SoFi Technologies, Tesla: Why These 5 Stocks Are On Investors' Radars Today - Benzinga
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring - ForexTV.com
S&P 500 Industrials [Sector] (SRIN) QuotePress Release - The Globe and Mail
TSX Composite Index (TXCX) QuotePress Release - The Globe and Mail
TSX Metals and Mining Capped Index (TTMN) QuotePress Release - The Globe and Mail
Company’s Banking Shares: Up -92.74% from 52-Week Low, But Can the Momentum Hold? - The InvestChronicle
Vivos stock surges on FDA nod for OSA device (NASDAQ:VVOS) - Seeking Alpha
Vivos Therapeutics rises on FDA approval for pediatric sleep apnea device - XM
What's Going On With TG Therapeutics Stock Wednesday? - Benzinga
Vivos Therapeutics Says It Is Poised To Disrupt Pediatric Sleep Apnea Market, Secures FDA Approval For DNA Appliance To Treat Snoring In Children - Benzinga
Vivos Therapeutics Shares Rally on FDA Clearance for Pediatric Sleep Apnea Treatment - MarketWatch
Vivos Therapeutics’ oral device approved by FDA for pediatric sleep apnea treatment - Proactive Investors UK
Stock Market Movers Today • Top Gainers & Losers - Benzinga
Vivos (VVOS) Stock Rallies In Pre-Hours Trading Following Key Regulatory Approval - Stocks Telegraph
Vivos gains FDA nod for child OSA treatment device - Investing.com
Vivos receives FDA 510k clearance to treat pediatric sleep apnea, snoring - TipRanks
Vivos Therapeutics Receives Groundbreaking FDA 510(k) Clearance to Treat Moderate to Severe Pediatric Sleep Apnea and Snoring - StockTitan
Target Hospitality Corp. Forecasted to Post FY2025 Earnings of $0.39 Per Share (NASDAQ:TH) - Defense World
Research Analysts Set Expectations for Huntington Ingalls Industries, Inc.’s Q2 2025 Earnings (NYSE:HII) - Defense World
Upbound Group, Inc. (NASDAQ:UPBD) Receives $40.25 Consensus Price Target from Brokerages - Defense World
Verint Systems Inc. (NASDAQ:VRNT) Short Interest Up 29.6% in August - Defense World
Los Angeles Capital Management LLC Sells 4,000 Shares of iTeos Therapeutics, Inc. (NASDAQ:ITOS) - Defense World
Los Angeles Capital Management LLC Grows Position in TPI Composites, Inc. (NASDAQ:TPIC) - Defense World
Vivos Therapeutics announces new equity incentive plan and executive agreements - Investing.com
Vivos Therapeutics Enhances Incentives and Executive Pay Structure - TipRanks
Vivos Therapeutics, Inc.'s (NASDAQ:VVOS) Shares Leap 41% Yet They're Still Not Telling The Full Story - Simply Wall St
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Short Interest Update - Defense World
3 Trending Biotech Penny Stocks - 24/7 Wall St.
VVOS Stock Earnings: Vivos Therapeutics Beats EPS, Beats Revenue for Q2 2024 - MSN
Ascendiant sees 180% upside in Vivos Therapeutics shares amid revenue rebound - Investing.com Canada
Earnings call: Vivos Therapeutics sees revenue and enrollment growth - Investing.com India
Earnings call: Vivos Therapeutics sees revenue and enrollment growth - Investing.com
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Q2 2024 Earnings Call Transcript - Insider Monkey
Q2 2024 Vivos Therapeutics Inc Earnings Call Transcript - Stockxpo
Vivos Secures Medicare Reimbursement and Launches New Marketing Strategy in Q2 - Sleep Review
Q2 2024 Vivos Therapeutics Inc Earnings Call Transcript - GuruFocus.com
Vivos Therapeutics boosts Q2 revenue, cuts operating losses amid new strategic partnerships - Proactive Investors USA
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update - ForexTV.com
Vivos Therapeutics Reports Second Quarter 2024 Financial Results and Provides Operational Update - StockTitan
Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call - ForexTV.com
Vivos Therapeutics Schedules Release of Second Quarter 2024 Financial Results and Conference Call - StockTitan
Best Biotech Penny Stocks Right Now • Updated Daily - Benzinga
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Significant Decrease in Short Interest - Defense World
Vivos Therapeutics, Inc. (NASDAQ:VVOS) Sees Significant Increase in Short Interest - Defense World
Vivos Therapeutics reports compliance plan to Nasdaq By Investing.com - Investing.com Canada
Citizens & Northern Corp director buys $4k in stock By Investing.com - Investing.com India
Kintara Therapeutics restructures share designations By Investing.com - Investing.com
Cathie Wood's ARK buys 10X Genomics, sells Zoom Video stock By Investing.com - Investing.com UK
Vivos Therapeutics reports compliance plan to Nasdaq - Investing.com
Fast Company Selects Vivos Therapeutics for 2022 “World’s Most Innovative Companies” List - Barchart
Vivos Therapeutics Schedules First Quarter 2022 Financial Results Conference Call - Barchart
Vivos gains as pilot program validates new market model - MSN
Vivos eyes human trials for radiation treatment gel with IDE submission - Clinical Trials Arena
Vivos Inc. Submits the Application to the FDA for Authority to Initiate Human Clinical Trials - StockTitan
Vivos stock gains on proof for market model (NASDAQ:VVOS) - Seeking Alpha
Vivos Therapeutics reports positive results from pilot of provider-based model - Proactive Investors UK
Vivos Therapeutics Reveals Positive Results From A 7-month, Multi-site Marketing Pilot, Testing Core Assumptions Behind Company's New Affiliation And Medical Sleep Specialist Marketing And Distribution Model - Quantisnow
Vivos Therapeutics Announces Positive Results From 7-Month Multi-Site Pilot of its New Provider-Based Marketing and ... - StockTitan
Carisma Therapeutics Announces Nomination of First In Vivo CAR-M Development Candidate for Hepatocellular Carcinoma Under Collaboration with Moderna - PR Newswire
Thinking about buying stock in Bellerophon Therapeutics, Orchard Therapeutics, ABVC Biopharma, KE Holdings, or ... - Marketscreener.com
0.08%
1.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Capitalizzazione:
|
Volume (24 ore):